Bn42083 A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study To Evaluate The Efficacy, Safety And Pharmacokinetics Of A Higher Dose Of Ocrelizumab In Adults With Primary Progressive Multiple Sclerosis
Posted Date: Feb 15, 2021
- Investigator: Aram Zabeti
- Specialties: Multiple Sclerosis, Neurology
- Type of Study: Drug
The primary efficacy objective is to demonstrate the superiority of a higher dose of ocrelizumab over the approved dose of ocrelizumab as assessed by risk reduction in cCDP sustained for at least 12 weeks.
Participant Must Be Between 18-55 That Has Been Diagnosed With Primary Progressive Multiple Sclerosis (Ppms) And Be Neurologically Stable For At Least 30 Days Prior To Randomization And Baseline Assessments.
Primary Progressive Multiple Sclerosis, Neurology, Ocrelizumab
For More Information: